qfx

Both Amazon and Alphabet, despite their lofty positions, are at the mercy of one inconvenient truth: the economy. Amazon, with its vast e-commerce empire, stands poised to suffer should the consumer pull back. In fact, when the inevitable economic slump arrives-and we all know it will-expect Amazon’s sales figures to mirror a falling soufflé. In Q2, a staggering 60% of Amazon’s revenue came from North American commerce, with another 22% trickling in from abroad. A delicate balance, indeed, where one gust of economic misfortune could spell disaster.

To uproot one’s strategy in the face of frost is folly. Instead, seek the trees whose bark resists decay, whose branches bend but do not snap. Here are five such saplings, grafted to the future’s uncertain soil.

Eli Lilly, ever the pragmatist, has unveiled data from trials that suggest its oral GLP-1 drug, orforglipron, may well be the phoenix rising from the ashes of previous contenders. While Novo Nordisk’s Rybelsus, the first oral GLP-1 treatment, was celebrated as a breakthrough in 2019, Lilly’s efforts have been met with a blend of skepticism and quiet confidence. The results, however, speak louder than the murmurs of doubt.

Even the most vigorous uptrends occasionally suffer a sprained ankle, especially when macroeconomic choreographers insist on changing the tempo. The transatlantic tariff tiff has spooked investors more than any blockchain flaw, though crypto’s aristocracy remains divided: some declare the party over, while others polish their monocles and whisper, “How vulgar to mistake a quadrille for a funeral march.”